Table 2.
C9+ Diagnosis subgroups | |||||
---|---|---|---|---|---|
Tract | Healthy controls N=28 | Asymptomatic N=7 | ALS N=11 | ALS-FTD N=7 | bvFTD N=3 |
R CST FA | 0.600 ± 0.023 | 0.604 ± 0.031 | 0.555 ± 0.034* | 0.580 ± 0.055 | 0.603 ± 0.033 |
R CST MD | 0.703 ± 0.022 | 0.701 ± 0.011 | 0.750 ± 0.035* | 0.753 ± 0.031* | 0.724 ± 0.019 |
L CST FA | 0.593 ± 0.028 | 0.590 ± 0.020 | 0.549 ± 0.030* | 0.585 ± 0.032 | 0.584 ± 0.018 |
L CST MD | 0.716 ± 0.021 | 0.711 ± 0.010 | 0.754 ± 0.029* | 0.768 ± 0.026* | 0.741 ± 0.020 |
R UNC FA | 0.435 ± 0.023 | 0.426 ± 0.009 | 0.424 ± 0.026 | 0.414 ± 0.027 | 0.403 ± 0.018 |
R UNC MD | 0.810 ± 0.022 | 0.820 ± 0.009 | 0.836 ± 0.024* | 0.876 ± 0.054* | 0.883 ± 0.052* |
L UNC FA | 0.432 ± 0.023 | 0.428 ± 0.019 | 0.424 ± 0.028 | 0.405 ± 0.038 | 0.412 ± 0.018 |
L UNC MD | 0.814 ± 0.027 | 0.824 ± 0.013 | 0.848 ± 0.034* | 0.875 ± 0.037* | 0.888 ± 0.041* |
CCg FA | 0.516 ± 0.032 | 0.525 ± 0.016 | 0.490 ± 0.025 | 0.481 ± 0.043 | 0.484 ± 0.053 |
CCg MD | 0.860 ± 0.039 | 0.852 ± 0.030 | 0.914 ± 0.029* | 0.991 ± 0.061* | 1.002 ± 0.140* |
CCpm FA | 0.542 ± 0.024 | 0.540 ± 0.007 | 0.514 ± 0.024* | 0.509 ± 0.037 | 0.488 ± 0.044* |
CCpm MD | 0.796 ± 0.036 | 0.796 ± 0.022 | 0.840 ± 0.046* | 0.906 ± 0.051* | 0.965 ± 0.187* |
CCm FA | 0.582 ± 0.017 | 0.578 ± 0.020 | 0.526 ± 0.032* | 0.535 ± 0.033* | 0.531 ± 0.031* |
CCm MD | 0.755 ± 0.029 | 0.766 ± 0.027 | 0.819 ± 0.052* | 0.849 ± 0.037* | 0.903 ± 0.162* |
CCsp FA | 0.611 ± 0.017 | 0.616 ± 0.013 | 0.602 ± 0.023 | 0.608 ± 0.014 | 0.609 ± 0.013 |
CCsp MD | 0.804 ± 0.031 | 0.803 ± 0.014 | 0.836 ± 0.034* | 0.869 ± 0.023* | 0.826 ± 0.038 |
Differs from healthy controls by ANCOVA (age as covariate), Dunnett’s test, adjusted p < 0.05.
ALS, amyotrophic lateral sclerosis; bvFTD, behavioural variant FTD; CCg, corpus callosum—genu; CCm, corpus callosum—motor; CCpm, corpus callosum—pre-motor; CCsp, corpus callosum—splenium; CST, corticospinal tract; FA, fractional anisotropy; L, left; MD, mean diffusivity; R, right; UNC, uncinate fasciculus.